A Phase II Study of Daily Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL.

Trial Profile

A Phase II Study of Daily Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (THRiL) as Initial Treatment for Patients With CLL.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Feb 2017

At a glance

  • Drugs Lenalidomide (Primary) ; Thalidomide (Primary) ; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Feb 2017 Planned End Date changed from 1 May 2014 to 1 May 2019.
    • 18 Apr 2011 Planned initiation date changed from 1 Feb 2011 to 1 May 2011 as reported by ClinicalTrials.gov.
    • 05 Jan 2011 Planned initiation date changed from 1 May 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top